Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369893 | 0.93 | RIPK1 (0.33) | LMNARIPK1 | |
| SCHEMBL4375502 | 0.90 | HTT (0.34) | LMNARIPK1MEN1KMT2A | |
| SCHEMBL4371149 | 0.88 | EPHX1 (0.35) | LMNARIPK1HRH1NPC1 | |
| SCHEMBL4379046 | 0.87 | TACR1 (0.35) | LMNARIPK1 | |
| SCHEMBL4368160 | 0.85 | LMNA (0.36) | LMNARIPK1TP53TAAR1HTR2A | |
| SCHEMBL4370146 | 0.85 | RIPK1 (0.42) | LMNARIPK1TAAR1HRH1MEN1 | |
| SCHEMBL4378617 | 0.84 | TP53 (0.37) | TP53MEN1KMT2A | |
| SCHEMBL4382020 | 0.84 | HTT (0.33) | MEN1KMT2A | |
| SCHEMBL4374013 | 0.84 | RIPK1 (0.37) | LMNARIPK1TP53AOC3HRH1 | |
| SCHEMBL4381058 | 0.82 | EPHX1 (0.33) | LMNARIPK1HRH1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
| EP-1323724-B1 | Ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-6790973-B2 | REDUCTION OF KETONE TO ALCOHOL USING COMPLEX CATALYST | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1323724-A2 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | Kanto Kagaku Kabushiki Kaisha (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | LMNA 3915/4885RIPK1 941/4885TP53 2744/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | LMNA 4608/4885RIPK1 590/4885TP53 4672/4885 |
| US-20030166978-A1 | Novel ruthenium complexes and process for preparing alcoholic compounds using these | ADH1C, ADH1A, ADH5 | LMNA 4207/4885RIPK1 1437/4885TP53 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.